1. Holmes VA, Young IS, Pat­ter­son CC, et al.; Di­a­betes and Pre-‍eclamp­sia In­ter­ven­tion Trial Study Group. Op­ti­mal glycemic con­trol, preeclamp­sia, and ges­ta­tion­al hy­per­ten­sion in women with type 1 di­a­betes in the Di­a­betes and Pre-‍eclamp­sia In­ter­ven­tion Trial. Di­a­betes Care 2011;34:1683–1688
2. Dabe­lea D, Han­son RL, Lind­say RS, et al. In­trauter­ine ex­po­sure to di­a­betes con­veys risks for type 2 di­a­betes and obe­si­ty: a study of dis­cor­dant sib­ships. Di­a­betes 2000;49:2208– 2211
3. Guerin A, Nisen­baum R, Ray JG. Use of ma­ter­nal GHb con­cen­tra­tion to es­ti­mate the risk of con­gen­i­tal anoma­lies in the off­spring of women with prepreg­nan­cy di­a­betes. Di­a­betes Care 2007;30:1920–1925
4. Jensen DM, Ko­r­sholm L, Ovesen P, et al. Pericon­cep­tional A1C and risk of se­ri­ous ad­verse preg­nan­cy out­come in 933 women with type 1 di­a­betes. Di­a­betes Care 2009;32:1046–1048
5. Nielsen GL, Møller M, Sørensen HT. HbA1c in early di­a­bet­ic preg­nan­cy and preg­nan­cy out­comes: a Dan­ish pop­u­la­tion-‍based co­hort study of 573 preg­nan­cies in women with type 1 di­a­betes. Di­a­betes Care 2006;29:2612–2616
6. Suho­nen L, Hi­iles­maa V, Ter­amo K. Gly­caemic con­trol dur­ing early preg­nan­cy and fetal mal­for­ma­tions in women with type I di­a­betes mel­li­tus. Di­a­betolo­gia 2000;43:79–82
7. Charron-‍Prochownik D, Serei­ka SM, Beck­er D, et al. Long-‍term ef­fects of the booster-en­hanced READY-‍Girls pre­con­cep­tion coun­sel­ing pro­gram on in­ten­tions and be­hav­iors for fam­i­ly plan­ning in teens with di­a­betes. Di­a­betes Care 2013;36: 3870–3874
8. Pe­ter­son C, Grosse SD, Li R, et al. Pre­ventable health and cost bur­den of ad­verse birth out­comes as­so­ci­at­ed with preges­ta­tion­al di­a­betes in the Unit­ed States. Am J Ob­stet Gy­necol 2015; 212:74.e1–74.e9
9. Charron-‍Prochownik D, Downs J. Di­a­betes and Re­pro­duc­tive Health for Girls. Alexan­dria, VA, Amer­i­can Di­a­betes As­so­ci­a­tion, 2016
10. Bullo M, Tschu­mi S, Buch­er BS, Bianchet­ti MG, Si­mon­et­ti GD. Preg­nan­cy out­come fol­lowing ex­po­sure to an­giotensin-converting en­zyme in­hibitors or an­giotensin re­cep­tor an­tag­o­nists: a sys­tematic re­view. Hy­per­ten­sion 2012;60: 444–450
11. Taguchi N, Rubin ET, Hosokawa A, et al. Pre­na­tal ex­po­sure to HMG-‍CoA re­duc­tase in­hibitors: ef­fects on fetal and neona­tal out­comes. Re­prod Tox­i­col 2008;26:175–177
12. Bate­man BT, Her­nan­dez-‍Diaz S, Fis­ch­er MA, et al. Statins and con­gen­i­tal mal­for­ma­tions: co­hort study. BMJ 2015;350:h1035
13. Chew EY, Mills JL, Met­zger BE, et al.; Na­tion­al In­sti­tute of Child Health and Human De­vel­op­ment Di­a­betes in Early Preg­nan­cy Study. Metabol­ic con­trol and pro­gres­sion of retinopa­thy: the Di­a­betes in Early Preg­nan­cy Study. Di­a­betes Care 1995;18:631–637
14. McElvy SS, Miodovnik M, Rosenn B, et al. A fo­cused pre­con­cep­tional and early preg­nan­cy pro­gram in women with type 1 di­a­betes re­duces peri­na­tal mor­tal­i­ty and mal­for­ma­tion rates to gen­er­al pop­u­la­tion lev­els. J Matern Fetal Med 2000;9:14–20
15. Mur­phy HR, Roland JM, Skin­ner TC, et al. Ef­fec­tiveness of a re­gion­al prepreg­nan­cy care pro­gram in women with type 1 and type 2 di­a­betes: benefits be­yond glycemic con­trol. Di­a­betes Care 2010;33:2514–2520
16. Elix­haus­er A, Weschler JM, Kitzmiller JL, et al. Cost-‍benefit anal­y­sis of pre­con­cep­tion care for women with es­tab­lished di­a­betes mel­li­tus. Di­a­betes Care 1993;16:1146–1157
17. Owens LA, Ava­l­os G, Kir­wan B, Car­mody L, Dunne F. AT­LANTIC DIP: clos­ing the loop: a change in clin­i­cal prac­tice can im­prove out­comes for women with preges­ta­tion­al di­a­betes. Di­a­betes Care 2012;35:1669–1671
18. Tay­lor C, Mc­Cance DR, Chap­pell L, Nel­son-‍ Pier­cy C, Thorne SA, Is­mail KMK, et al. Im­ple­men­ta­tion of guide­lines for mul­ti­dis­ci­plinary team man­age­ment of preg­nan­cy in women with pre-‍ex­ist­ing di­a­betes or car­diac con­di­tions: re­sults from a UK na­tion­al sur­vey. BMC Preg­nan­cy Child­birth 2017;17:434
19. Man­der­son JG, Pat­ter­son CC, Had­den DR, Traub AI, Ennis C, Mc­Cance DR. Prepran­di­al ver­sus post­pran­di­al blood glu­cose mon­i­tor­ing in type 1 di­a­bet­ic preg­nan­cy: a ran­dom­ized con­trolled clin­i­cal trial. Am J Ob­stet Gy­necol 2003;189:507–512
20. de Ve­ciana M, Major CA, Mor­gan MA, et al. Post­pran­di­al ver­sus prepran­di­al blood glu­cose mon­i­tor­ing in women with ges­ta­tion­al di­a­betes mel­li­tus re­quir­ing in­sulin ther­apy. N Engl J Med 1995;333:1237–1241
21. Jo­vanovic-Pe­ter­son L, Pe­ter­son CM, Reed GF, et al. Ma­ter­nal post­pran­di­al glu­cose lev­els and in­fant birth weight: the Di­a­betes in Early Preg­nan­cy Study. The Na­tion­al In­sti­tute of Child Health and Human De­vel­op­ment–Di­a­betes in Early Preg­nan­cy Study. Am J Ob­stet Gy­necol 1991;164:103–111
22. Com­mit­tee on Prac­tice Bul­letinsdOb­stetrics. ACOG Prac­tice Bul­letin No. 190: Ges­ta­tion­al Di­a­betes Mel­li­tus. Ob­stet Gy­necol 2018;131: e49–e64
23. Ho Y-R, Wang P, Lu M-C, Tseng S-T, Yang C-P, Yan Y-H. As­so­ci­a­tions of mid-‍preg­nan­cy HbA1c with ges­ta­tion­al di­a­betes and risk of ad­verse preg­nan­cy out­comes in high-‍risk Tai­wanese women. PLoS One 2017;12:e0177563
24. Met­zger BE, Lowe LP, Dyer AR, et al.; HAPO Study Co­op­er­a­tive Re­search Group. Hy­per­glycemia and ad­verse preg­nan­cy out­comes. N Engl J Med 2008;358:1991–2002
25. Maresh MJA, Holmes VA, Pat­ter­son CC, et al.; Di­a­betes and Pre-‍eclamp­sia In­ter­ven­tion Trial Study Group. Glycemic tar­gets in the sec­ond and third trimester of preg­nan­cy for women with type 1 di­a­betes. Di­a­betes Care 2015;38:34–42
26. Nielsen LR, Ekbom P, Damm P, et al. HbA1c lev­els are significant­ly lower in early and late preg­nan­cy. Di­a­betes Care 2004;27:1200–1201
27. Mosca A, Paleari R, Dal­fra` MG, et al. Ref- er­ence in­ter­vals for hemoglobin A1c in preg­nant women: data from an Ital­ian multicen­ter study. Clin Chem 2006;52:1138–1143
28. Hum­mel M, Marien­feld S, Hupp­mann M, et al. Fetal growth is in­creased by ma­ter­nal type 1 di­a­betes and HLA DR4-‍re­lat­ed gene in­ter­ac­tions. Di­a­betolo­gia 2007;50:850–858
29. Cy­ganek K, Skupi­en J, Katra B, et al. Risk of macro­so­mia re­mains glu­cose-dependent in a co­hort of women with preges­ta­tion­al type 1 di­a­betes and good glycemic con­trol. En­docrine 2017;55:447–455
30. Abell SK, Boyle JA, de Courten B, et al. Im­pact of type 2 di­a­betes, obe­si­ty and gly­caemic con­trol on preg­nan­cy out­comes. Aust N Z J Ob­stet Gy­naecol 2017;57:308–314
31. Tem­ple RC, Aldridge V, Stan­ley K, Mur­phy HR. Gly­caemic con­trol through­out preg­nan­cy and risk of pre-‍eclamp­sia in women with type I di­a­betes. BJOG 2006;113:1329–1332
32. Combs CA, Gun­der­son E, Kitzmiller JL, Gavin LA, Main EK. Re­la­tion­ship of fetal macro­so­mia to ma­ter­nal post­pran­di­al glu­cose con­trol dur­ing preg­nan­cy. Di­a­betes Care 1992;15:1251– 1257
33. Bain E, Crane M, Tieu J, Han S, Crowther CA, Mid­dle­ton P. Diet and ex­er­cise in­ter­ven­tions for pre­vent­ing ges­ta­tion­al di­a­betes mel­li­tus. Cochrane Database Syst Rev 2015;4:CD010443
34. Koivusa­lo SB, Ro¨no¨ K, Klemet­ti MM, et al. Ges­ta­tion­al di­a­betes mel­li­tus can be pre­vented by lifestyle in­ter­ven­tion: the Finnish Ges­ta­tion­al Di­a­betes Pre­ven­tion Study (RADIEL): a ran­dom­ized con­trolled trial. Di­a­betes Care 2016;39:24– 30
35. Wang C, Wei Y, Zhang X, et al. A ran­dom­ized clin­i­cal trial of ex­er­cise dur­ing preg­nan­cy to pre­vent ges­ta­tion­al di­a­betes mel­li­tus and im­prove preg­nan­cy out­come in over­weight and obese preg­nant women. Am J Ob­stet Gy­necol 2017;216:340–351
36. Met­zger BE, Buchanan TA, Cous­tan DR, et al. Sum­ma­ry and rec­om­men­da­tions of the Fifth In­ter­na­tion­al Work­shop-‍Con­fer­ence on Ges­ta­tion­al Di­a­betes Mel­li­tus. Di­a­betes Care;2007;30 (Suppl. 2):S251–S260
37. Mayo K, Melamed N, Van­den­berghe H, Berg­er H. The im­pact of adop­tion of the In­ter­na­tion­al As­so­ci­a­tion of Di­a­betes in Preg­nan­cy Study Group cri­te­ria for the screen­ing and di­ag­no­sis of ges­ta­tion­al di­a­betes. Am J Ob­stet Gy­necol 2015;212:224.e1–224.e9
38. Han S, Crowther CA, Mid­dle­ton P, Heat­ley E. Dif­fer­ent types of di­etary ad­vice for women with ges­ta­tion­al di­a­betes mel­li­tus. Cochrane Database Syst Rev 2013;3:CD009275
39. Viana LV, Gross JL, Azeve­do MJ. Di­etary in­ter­ven­tion in pa­tients with ges­ta­tion­al di­a­betes mel­li­tus: a sys­tematic re­view and meta­anal­y­sis of ran­dom­ized clin­i­cal tri­als on ma­ter­nal and new­born out­comes. Di­a­betes Care 2014;37: 3345–3355
40. Hartling L, Dry­den DM, Guthrie A, Muise M, Van­der­meer B, Dono­van L. Benefits and harms of treat­ing ges­ta­tion­al di­a­betes mel­li­tus: a sys­tematic re­view and meta-‍anal­y­sis for the U.S. Pre­ven­tive Ser­vices Task Force and the Na­tion­al In­sti­tutes of Health Office of Med­i­cal Ap­pli­ca­tions of Re­search. Ann In­tern Med 2013;159: 123–129
41. Rowan JA, Hague WM, Gao W, Bat­tin MR, Moore MP; MiG Trial In­ves­ti­ga­tors. Met­formin ver­sus in­sulin for the treat­ment of ges­ta­tion­al di­a­betes. N Engl J Med 2008;358:2003–2015
42. Gui J, Liu Q, Feng L. Met­formin vs in­sulin in the man­age­ment of ges­ta­tion­al di­a­betes: a meta-‍anal­y­sis. PLoS One 2013;8:e64585
43. Langer O, Con­way DL, Berkus MD, Xe­nakis EM-J, Gon­za­les O. A com­par­i­son of gly­buride and in­sulin in women with ges­ta­tion­al di­a­betes mel­li­tus. N Engl J Med 2000;343:1134–1138
44. Hebert MF, Ma X, Nara­hariset­ti SB, et al.; Ob­stetric-Fetal Phar­ma­col­o­gy Re­search Unit Net­work. Are we op­ti­miz­ing ges­ta­tion­al di­a­betes treat­ment with gly­buride? The phar­ma­co­log­ic basis for bet­ter clin­i­cal prac­tice. Clin Phar­ma­col Ther 2009;85:607–614
45. Malek R, Davis SN. Pharmacoki­net­ics, effi- cacy and safe­ty of gly­buride for treat­ment of ges­ta­tion­al di­a­betes mel­li­tus. Ex­pert Opin Drug Metab Tox­i­col 2016;12:691–699
46. Balsells M, Garc´ıa-‍Pat­ter­son A, Sola` I, Roque´ M, Gich I, Cor­coy R. Gliben­clamide, met­formin, and in­sulin for the treat­ment of ges­ta­tion­al di­a­betes: a sys­tematic re­view and meta-‍anal­y­sis. BMJ 2015;350:h102
47. Cous­tan DR. Phar­ma­co­log­ical man­age­ment of ges­ta­tion­al di­a­betes: an overview. Di­a­betes Care 2007;30(Suppl. 2):S206–S208
48. Se´nat M-V, Af­fres H, Le­tourneau A, et al.; Groupe de Recherche en Obste´trique et Gyne´colo­gie (GROG). Ef­fect of gly­buride vs sub­cu­ta­neous in­sulin on peri­na­tal com­pli­ca­tions among women with ges­ta­tion­al di­a­betes: a ran­dom­ized clin­i­cal trial. JAMA 2018;319:1773– 1780
49. Jiang Y-F, Chen X-Y, Ding T, Wang X-F, Zhu Z-N, Su S-W. Com­par­a­tive efficacy and safe­ty of OADs in man­age­ment of GDM: net­work meta-‍anal­y­sis of ran­dom­ized con­trolled tri­als. J Clin En­docrinol Metab 2015;100:2071–2080
50. Came­lo Castil­lo W, Boggess K, Stu¨rmer T, Brookhart MA, Ben­jamin DK Jr, Jon­s­son Funk M. As­so­ci­a­tion of ad­verse preg­nan­cy out­comes with gly­buride vs in­sulin in women with ges­ta­tion­al di­a­betes. JAMA Pe­di­atr 2015;169:452–458
51. Vanky E, Zahlsen K, Spigset O, Carlsen SM. Pla­cen­tal pas­sage of met­formin in women with poly­cys­tic ovary syn­drome. Fer­til Ster­il 2005; 83:1575–1578
52. Charles B, Nor­ris R, Xiao X, Hague W. Pop­u­la­tion pharmacoki­net­ics of met­formin in late preg­nan­cy. Ther Drug Monit 2006;28:67–72
53. Rowan JA, Rush EC, Plank LD, et al. Met­formin in Ges­ta­tion­al Di­a­betes: The Off­spring Fol­low-‍Up (MiG TOFU): body com­po­si­tion and metabol­ic out­comes at 7-9 years of age. BMJ Open Di­a­betes Res Care 2018;6:e000456
54. Hanem LGE, Strid­sklev S, Ju´l´ıusson PB, et al. Met­formin use in PCOS preg­nan­cies in­creases the risk of off­spring over­weight at 4 years of age: fol­low-‍up of two RCTs. J Clin En­docrinol Metab 2018;103:1612–1621
55. Vanky E, Strid­sklev S, Heim­stad R, et al. Met­formin ver­sus place­bo from first trimester to de­liv­ery in poly­cys­tic ovary syn­drome: a ran­dom­ized, con­trolled multicen­ter study. J Clin En­docrinol Metab 2010;95:E448–E455
56. Legro RS, Barn­hart HX, Schlaff WD, et al.; Co­op­er­a­tive Multicen­ter Re­pro­duc­tive Medicine Net­work. Clomiphene, met­formin, or both for in­fer­til­i­ty in the poly­cys­tic ovary syn­drome. N Engl J Med 2007;356:551–566
57. Palom­ba S, Orio F Jr, Falbo A, et al. Prospec­tive par­al­lel ran­dom­ized, dou­ble-‍blind, dou­ble-‍dummy con­trolled clin­i­cal trial com­par­ing clomiphene cit­rate and met­formin as the first-‍line treat­ment for ovu­la­tion in­duc­tion in non-‍obese anovu­la­to­ry women with poly­cys­tic ovary syn­drome. J Clin En­docrinol Metab 2005; 90:4068–4074
58. Palom­ba S, Orio F Jr, Nardo LG, et al. Met- formin ad­min­is­tra­tion ver­sus la­paro­scop­ic ovar­i­an diathermy in clomiphene cit­rate-resistant women with poly­cys­tic ovary syn­drome: a prospec­tive par­al­lel ran­dom­ized dou­ble-‍blind place­bo-‍con­trolled trial. J Clin En­docrinol Metab 2004; 89:4801–4809
59. Far­rar D, Tuffnell DJ, West J, West HM. Con­tin­u­ous sub­cu­ta­neous in­sulin in­fu­sion ver­sus mul­ti­ple daily injec­tions of in­sulin for preg­nant women with di­a­betes. Cochrane Database Syst Rev 2016;6:CD005542
60. Garc´ıa-‍Pat­ter­son A, Gich I, Amini SB, Cata­lano PM, de Leiva A, Cor­coy R. In­sulin re­quire­ments through­out preg­nan­cy in women with type 1 di­a­betes mel­li­tus: three changes of direc­tion. Di­a­betolo­gia 2010;53:446–451
61. Menon RK, Cohen RM, Sper­ling MA, Cutfield WS, Mi­mouni F, Khoury JC. Transpla­cen­tal pas­sage of in­sulin in preg­nant women with in­sulin-dependent di­a­betes mel­li­tus. Its role in fetal macro­so­mia. N Engl J Med 1990;323:309–315
62. Pollex EK, Feig DS, Lu­bet­sky A, Yip PM, Koren G. In­sulin glargine safe­ty in preg­nan­cy: a transpla­cen­tal trans­fer study. Di­a­betes Care 2010;33: 29–33
63. Hol­cberg G, Tsadkin-‍Tamir M, Sapir O, et al. Trans­fer of in­sulin lispro across the human pla­cen­ta. Eur J Ob­stet Gy­necol Re­prod Biol 2004;115:117–118
64. Boskovic R, Feig DS, Derewlany L, Knie B, Port­noi G, Koren G. Trans­fer of in­sulin lispro across the human pla­cen­ta: in vitro per­fu­sion stud­ies. Di­a­betes Care 2003;26:1390–1394
65. Mc­Cance DR, Damm P, Math­iesen ER, et al. Eval­u­a­tion of in­sulin an­ti­bod­ies and pla­cen­tal trans­fer of in­sulin as­part in preg­nant women with type 1 di­a­betes mel­li­tus. Di­a­betolo­gia 2008; 51:2141–2143
66. Suf­fe­cool K, Rosenn B, Niederkofler EE, et al. In­sulin de­temir does not cross the human pla­cen­ta. Di­a­betes Care 2015;38:e20–e21
67. O’Neill SM, Kenny LC, Khashan AS, West HM, Smyth RM, Kear­ney PM. Dif­fer­ent in­sulin types and reg­i­mens for preg­nant women with pre­ex­ist­ing di­a­betes. Cochrane Database Syst Rev 2017;2:CD011880
68. Duckitt K, Har­ring­ton D. Risk fac­tors for preeclamp­sia at an­te­na­tal book­ing: sys­tematic re­view of con­trolled stud­ies. BMJ 2005;330:565
69. Hen­der­son JT, Whit­lock EP, O’Con­ner E, Sen­ger CA, Thomp­son JH, Row­land MG. Low-‍dose as­pirin for the pre­vention of mor­bid­i­ty and mor­tal­i­ty from preeclamp­sia: a sys­tematic ev­i­dence re­view for the U.S. Pre­ven­tive Ser­vices Task Force, 2014. Rockville, MD, Agen­cy for Health­care Re­search and Qual­i­ty (Re­port No. 14-05207-EF-1)
70. Wern­er EF, Haus­purg AK, Rouse DJ. A cost-‍benefit anal­y­sis of low-‍dose as­pirin pro­phy­lax­is for the pre­vention of preeclamp­sia in the Unit­ed States. Ob­stet Gy­necol 2015;126:1242–1250
71. Feig DS, Dono­van LE, Cor­coy R, et al.; CON­CEPTT Col­lab­o­ra­tive Group. Con­tin­u­ous glu­cose mon­i­tor­ing in preg­nant women with type 1 di­a­betes (CON­CEPTT): a mul­ti­cen­tre interna­tion­al ran­domised con­trolled trial. Lancet 2017;390:2347–2359
72. In­sti­tute of Medicine and Na­tion­al Re­search Coun­cil. Weight Gain Dur­ing Preg­nan­cy: Re­ex­am­in­ing the Guide­lines. Wash­ing­ton, DC, Na­tion­al Academies Press, 2009
73. Clausen TD, Math­iesen E, Ekbom P, Hell­muth E, Mandrup-‍Poulsen T, Damm P. Poor preg­nan­cy out­come in women with type 2 di­a­betes. Di­a­betes Care 2005;28:323–328
74. Cundy T, Gam­ble G, Neale L, et al. Dif­fer­ing caus­es of preg­nan­cy loss in type 1 and type 2 di­a­betes. Di­a­betes Care 2007;30:2603–2607
75. Amer­i­can Col­lege of Ob­ste­tri­cians and Gy- ne­col­o­gists; Task Force on Hy­per­ten­sion in Preg­nan­cy. Hy­per­ten­sion in preg­nan­cy. Re­port of the Amer­i­can Col­lege of Ob­ste­tri­cians and Gy­ne­col­o­gists’ Task Force on Hy­per­ten­sion in Preg­nan­cy. Ob­stet Gy­necol 2013;122:1122–1131
76. Magee LA, von Dadel­szen P, Rey E, et al. Less-‍tight ver­sus tight con­trol of hy­per­ten­sion in preg­nan­cy. N Engl J Med 2015;372:407–417
77. Sibai BM. Treat­ment of hy­per­ten­sion in preg­nant women. N Engl J Med 1996;335: 257–265
78. Kazmin A, Gar­cia-‍Bournissen F, Koren G. Risks of statin use dur­ing preg­nan­cy: a sys­tematic re­view. J Ob­stet Gy­naecol Can 2007;29:906–908
79. Stuebe AM, Rich-‍Ed­wards JW, Wil­lett WC, Man­son JE, Michels KB. Du­ra­tion of lac­ta­tion and in­ci­dence of type 2 di­a­betes. JAMA 2005; 294:2601–2610
80. Pereira PF, Alfe­nas Rde CG, Arau´jo RMA. Does breast­feed­ing influence the risk of de­vel­oping di­a­betes mel­li­tus in chil­dren? A re­view of cur­rent ev­i­dence. J Pe­di­atr (Rio J) 2014; 90:7–15
81. Kim C, New­ton KM, Knopp RH. Ges­ta­tion­al di­a­betes and the in­ci­dence of type 2 di­a­betes: a sys­tematic re­view. Di­a­betes Care 2002;25: 1862–1868
82. Drury MI. Car­bo­hy­drate metabolism in preg­nan­cy and the new­born. Suther­land HW, Stow­ers JM, Eds. Ed­in­burgh, Churchill Liv­ing­stone, 1984
83. To­bias DK, Hu FB, Chavar­ro J, Ros­ner B, Mozaf­far­i­an D, Zhang C. Health­ful di­etary pat­terns and type 2 di­a­betes mel­li­tus risk among women with a his­to­ry of ges­ta­tion­al di­a­betes mel­li­tus. Arch In­tern Med 2012;172:1566–1572
84. Vil­lam­or E, Cnat­tingius S. Interpreg­nan­cy weight change and risk of ad­verse preg­nan­cy out­comes: a pop­u­la­tion-‍based study. Lancet 2006;368:1164–1170
85. Rat­ner RE, Christophi CA, Met­zger BE, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. Pre­ven­tion of di­a­betes in women with a his­to­ry of ges­ta­tion­al di­a­betes: ef­fects of met­formin and lifestyle in­ter­ven­tions. J Clin En­docrinol Metab 2008;93:4774–4779
86. Aroda VR, Christophi CA, Edel­stein SL, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. The ef­fect of lifestyle in­ter­ven­tion and met­formin on pre­vent­ing or de­lay­ing di­a­betes among women with and with­out ges­ta­tion­al di­a­betes: the Di­a­betes Pre­ven­tion Pro­gram Out­comes Study 10-year fol­low-‍up. J Clin En­docrinol Metab 2015;100:1646–1653
87. Roed­er HA, Moore TR, Ramos GA. Changes in post­par­tum in­sulin re­quire­ments for pa­tients with well-‍con­trolled type 1 di­a­betes. Am J Peri­na­tol 2016;33:683–687
88. Riv­iel­lo C, Mello G, Jo­vanovic LG. Breastfeed-‍ ing and the basal in­sulin re­quirement in type 1 di­a­bet­ic women. En­docr Pract 2009;15:187– 193